VR Logo

Nymox Pharmaceutical Corporation (Bahamas) - ADR download report


Healthcare | Biotechnology & Pharma Research

Nymox Pharmaceutical Corporation (Bahamas) - ADR Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally.

IPO Date: 01-Dec-1997

Founder, Chairman, CEO & Pres: Dr. Paul Averback DABP, M.D.

CFO & Controller: Mr. Erik Danielsen

Listing: NASDAQ: NYMX

Country: Bahamas

Headquarters: Nassau,

Website: https://nymox.com

Key Facts

Market cap: $40.51 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-15.18 Mln

Cash: $0.67 Mln

Total Debt: $0.34 Mln

Insider's Holding: 45.15%

Liquidity: Low

52 Week range: $0.35 - 2.27

Shares outstanding: 90,280,000

10 Years Aggregate:

  • CFO: $-70.08 Mln
  • EBITDA: $-107.80 Mln
  • Net Profit: $-109.59 Mln

Stock Performance

Time Period Nymox Pharmaceutical Corporation (Bahamas) - ADR S&P BSE Sensex* S&P Small-Cap 600*
YTD-64.52-8.71-17.14
1 month9.57-3.11-4.85
3 months-61.88-7.30-12.74
1 Year-71.520.48-16.37
3 Years-32.8010.347.97
5 Years-34.9511.436.33
10 Years-23.2812.1010.54
As on 27-Jun-2022 *As on 28-Jun-2022
Year Nymox Pharmaceutical Corporation (Bahamas) - ADR S&P Small-Cap 600 S&P BSE Sensex
2021-47.5825.2721.99
202012.739.5715.75
201967.9420.8614.38
2018-60.10-9.705.87
201723.6011.7327.91
2016-18.6024.741.95
2015720.00-3.36-5.03